OPT-EPA
Research type
Research Study
Full title
Optimizing Patient Treatment with EPA-enriched Nutrition, a randomised control trial – OPT-EPA
IRAS ID
356516
Contact name
Richard Skipworth
Contact email
Sponsor organisation
University of Edinburgh
Duration of Study in the UK
1 years, 9 months, 2 days
Research summary
The OPT-EPA study looks at the use of oral nutritional supplements (ONS) in patients living with either colorectal or lung cancer at stage III or IV. Malnutrition is a common and serious issue for people living cancer. Many cancer patients experience weight loss, muscle weakness and poor quality of life due to malnutrition. This can also reduce the success of cancer treatments, increase hospital visits, and add emotional distress for both patients and their loved ones.
Treating malnutrition through good nutritional care is increasingly recognised as an important part of cancer treatment. Leading experts recommend that all cancer patients be checked for signs of malnutrition and given personalised nutrition plans when necessary. While dietary counselling and oral nutritional supplements (ONS) are often used to help patients, there is still a need for better evidence to show how well these interventions work.
A key factor contributing to malnutrition in cancer patients is inflammation. Omega-3 fatty acids, (like those found in oily fish) are known for their anti-inflammatory properties. Some studies suggest that omega-3s may help cancer patients by reducing inflammation, keeping muscles strong, improving appetite, and enhancing overall well-being.The OPT-EPA trial will investigate whether a nutritional drink, called Fortimel Forticare Sensations (FFS), can improve nutritional status in patients with lung or colorectal cancer who are at risk of malnutrition. This drink is enriched with omega-3 fatty acids (EPA and DHA) and provides a high amount of protein and calories in a small volume, making it easier to consume, especially for patients with taste changes.
One group will receive dietary counselling along with the omega-3-enriched nutritional drink, while the other group will receive dietary counselling alone, with supplements provided only if clinically necessary.
Through the OPT-EPA trial, researchers hope to gain clearer insights into whether omega-3-containing supplements can provide meaningful benefits for cancer patients. Ultimately, this could help improve the quality of care and outcomes for people facing cancer-related malnutrition.REC name
South East Scotland REC 02
REC reference
25/SS/0082
Date of REC Opinion
26 Nov 2025
REC opinion
Further Information Favourable Opinion